WallStreetZenWallStreetZen

NASDAQ: ONCY
Oncolytics Biotech Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for ONCY

Based on 2 analysts offering 12 month price targets for Oncolytics Biotech Inc

Min Forecast
$7.00+736.32%
Avg Forecast
$8.50+915.53%
Max Forecast
$10.00+1,094.74%

Should I buy or sell ONCY stock?

Based on 2 analysts offering ratings for Oncolytics Biotech Inc.

Strong Buy
Strong Buy
1 analysts 50%
Buy
1 analysts 50%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although ONCY's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates ONCY as a "Strong Sell". Stocks with a Zen Rating of Strong Sell have had an average return of -8.02% per year. Learn More

Be the first to know when Wall Street analysts revise their ONCY stock forecasts and price targets.

ONCY stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-11-17
lockedlocked$00.00+00.00%2025-08-13

1 of 1

Forecast return on equity

Is ONCY forecast to generate an efficient return?

Company
N/A
Industry
338.26%
Market
218.22%

Forecast return on assets

Is ONCY forecast to generate an efficient return on assets?

Company
N/A
Industry
120%

ONCY earnings per share forecast

What is ONCY's earnings per share in the next 2 years based on estimates from 6 analysts?

Avg 1 year Forecast
-$0.35
Avg 2 year Forecast
-$0.27

ONCY revenue forecast

What is ONCY's revenue in the next 3 years based on estimates from 6 analysts?

Avg 1 year Forecast
$2.0M
Avg 2 year Forecast
$52.6M
Avg 3 year Forecast
$34.7M

ONCY vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
ONCY$0.84$8.50+915.53%Strong Buy
CGTX$1.00$3.33+233.30%Strong Buy
GNLX$2.35$16.00+580.85%Strong Buy
VANI$1.23$4.00+225.20%Buy
INO$1.56$4.50+188.46%Buy
View Top Biotech Stocks

Oncolytics Biotech Stock Forecast FAQ

Is Oncolytics Biotech Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NASDAQ: ONCY) stock is to Strong Buy ONCY stock.

Out of 2 analysts, 1 (50%) are recommending ONCY as a Strong Buy, 1 (50%) are recommending ONCY as a Buy, 0 (0%) are recommending ONCY as a Hold, 0 (0%) are recommending ONCY as a Sell, and 0 (0%) are recommending ONCY as a Strong Sell.

If you're new to stock investing, here's how to buy Oncolytics Biotech stock.

What is ONCY's earnings growth forecast for 2026-2027?

(NASDAQ: ONCY) Oncolytics Biotech's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 70.01%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 40.01%.

Oncolytics Biotech's earnings in 2026 is -$25,192,142.On average, 6 Wall Street analysts forecast ONCY's earnings for 2026 to be -$36,635,232, with the lowest ONCY earnings forecast at -$39,609,578, and the highest ONCY earnings forecast at -$30,468,906.

In 2027, ONCY is forecast to generate -$28,261,465 in earnings, with the lowest earnings forecast at -$42,656,468 and the highest earnings forecast at -$13,058,102.

What is ONCY's revenue growth forecast for 2026-2028?

(NASDAQ: ONCY) Oncolytics Biotech's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 117.31%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 22.77%.

Oncolytics Biotech's revenue in 2026 is $0.On average, 6 Wall Street analysts forecast ONCY's revenue for 2026 to be $209,344,183, with the lowest ONCY revenue forecast at $0, and the highest ONCY revenue forecast at $652,905,124. On average, 5 Wall Street analysts forecast ONCY's revenue for 2027 to be $5,453,415,959, with the lowest ONCY revenue forecast at $0, and the highest ONCY revenue forecast at $11,338,785,657.

In 2028, ONCY is forecast to generate $3,600,409,035 in revenue, with the lowest revenue forecast at $1,147,765,754 and the highest revenue forecast at $6,256,178,354.

What is ONCY's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: ONCY) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of 120%.

What is ONCY's Price Target?

According to 2 Wall Street analysts that have issued a 1 year ONCY price target, the average ONCY price target is $8.50, with the highest ONCY stock price forecast at $10.00 and the lowest ONCY stock price forecast at $7.00.

On average, Wall Street analysts predict that Oncolytics Biotech's share price could reach $8.50 by Nov 17, 2026. The average Oncolytics Biotech stock price prediction forecasts a potential upside of 915.53% from the current ONCY share price of $0.84.

What is ONCY's Earnings Per Share (EPS) forecast for 2026-2027?

(NASDAQ: ONCY) Oncolytics Biotech's current Earnings Per Share (EPS) is -$0.28. On average, analysts forecast that ONCY's EPS will be -$0.35 for 2026, with the lowest EPS forecast at -$0.38, and the highest EPS forecast at -$0.29. In 2027, ONCY's EPS is forecast to hit -$0.27 (min: -$0.41, max: -$0.13).

What is ONCY's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: ONCY) forecast ROE is N/A, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.